Aquilo Capital Management LLC recently announced the acquisition of new stake in Pieris Pharmaceuticals Inc. (NASDAQ:PIRS). The institutional investor has increased its shareholding in the Healthcare company by 8.03% to 4.04 million shares with purchase of 0.3 million shares. This fresh investment now brings its stake to 5.60% valued currently at $4.48 million. In addition, Lynx1 Capital Management LP raised its holdings by 0.31 million to 3.82 million shares. And Platinum Investment Management Lt has lifted its position by 11.09% or 0.12 million shares – to 1.22 million shares.
With over 4.31 million Pieris Pharmaceuticals Inc. (PIRS) shares trading Tuesday and a closing price of $0.94 on the day, the dollar volume was approximately $4.05 million. The shares have shown a negative half year performance of -43.31% and its price on 11/22/22 lost nearly -1.73%. Currently, there are 74.40M common shares owned by the public and among those 67.07M shares have been available to trade.
Insiders at the company have transacted a total of 1 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 6,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Pieris Pharmaceuticals Inc. are Candriam Equities L – Biotechnolo, FCP Medical – BioHealth, and Vanguard Extended Market Index Fu. Candriam Equities L – Biotechnolo owns 1.06 million shares of the company’s stock, all valued at over $1.18 million. Vanguard Extended Market Index Fu now owns shares totaling to 1.21% of the shares outstanding.
However, the script later moved the day high at 0.9800, down -1.73%. The company’s stock has a 5-day price change of -3.51% and -40.44% over the past three months. PIRS shares are trading -75.10% year to date (YTD), with the 12-month market performance down to -73.42% lower. It has a 12-month low price of $0.92 and touched a high of $4.08 over the same period. PIRS has an average intraday trading volume of 164.92K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.09%, -14.05%, and -53.10% respectively.
Institutional ownership of Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) shares accounts for 55.40% of the company’s 74.40M shares outstanding. Mutual fund holders own 43.73%, while other institutional holders and individual stakeholders account for 7.49% and 15.62% respectively.
It has a market capitalization of $71.50M and a beta (3y monthly) value of 1.04. The earnings-per-share (ttm) stands at -$0.47. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.79% over the week and 7.40% over the month.
Analysts forecast that Pieris Pharmaceuticals Inc. (PIRS) will achieve an EPS of -$0.16 for the current quarter, -$0.23 for the next quarter and -$0.6 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.19 while analysts give the company a high EPS estimate of -$0.13. Comparatively, EPS for the current quarter was -$0.24 a year ago. Earnings per share for the fiscal year are expected to decrease by -3.70%, and 0.00% over the next financial year.
Looking at the support for the PIRS, a number of firms have released research notes about the stock. Robert W. Baird stated their Outperform rating for the stock in a research note on March 13, 2020, with the firm’s price target at $5. Robert W. Baird was of a view on May 14, 2019 that the stock is Outperform, while Jefferies gave the stock Buy rating on March 19, 2018, issuing a price target of $12. Evercore ISI on their part issued Outperform rating on March 19, 2018.